Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Clinical Oncology

• Publication date

  2012-09-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.41.3807PMID 22869886PMCID PMC3434986
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

  2012cited by this paper
• Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.

  2012cited by this paper
• Cancer immunotherapy.

  2011cited by this paper
• Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.

  2011cited by this paper
• Multifactorial central nervous system recurrence susceptibility in patients with HER2‐positive breast cancer

  2011cited by this paper
• Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

  2010cited by this paper
• Recent advances in neuroblastoma.

  2010cited by this paper
• Abstract 5586: NK cell killer Ig-like receptor (KIR) genotype as a novel biomarker for neuroblastoma patients receiving Anti-GD2 monoclonal antibody 3F8

  2010cited by this paper
• Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors

  2010cited by this paper
• Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

  2010cited by this paper
• Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma

  2010cited by this paper
• Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

  2009cited by this paper
• KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma

  2009cited by this paper
• Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study.

  2009cited by this paper
• Late effects in survivors of tandem peripheral blood stem cell transplant for high‐risk neuroblastoma

  2008cited by this paper
• Exploiting Gene Expression Profiling to Identify Novel Minimal Residual Disease Markers of Neuroblastoma

  2008cited by this paper
• Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

  2008cited by this paper
• 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures

  2008cited by this paper
• High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.

  2008cited by this paper
• The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.

  2008cited by this paper
• Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

  2008cited by this paper
• Inhibitory KIR–HLA receptor–ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma

  2007cited by this paper
• Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review.

  2007cited by this paper
• Disialoganglioside Directed Immunotherapy of Neuroblastoma

  2007cited by this paper
• Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.

  2007cited by this paper
• High‐dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: Broad implications for immunotherapy

  2007cited by this paper
• Single-agent interleukin-2 in the treatment of metastatic melanoma

  2007cited by this paper
• FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.

  2006cited by this paper
• Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system

  2006cited by this paper
• Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

  2006cited by this paper
• High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.

  2006cited by this paper
• Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma.

  2004cited by this paper
• Camptothecin Analogs (Irinotecan or Topotecan) plus High-Dose Cyclophosphamide as Preparative Regimens for Antibody-Based Immunotherapy in Resistant Neuroblastoma

  2004cited by this paper
• Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.

  2004cited by this paper
• Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.

  2003cited by this paper
• Central nervous system metastases in neuroblastoma

  2003cited by this paper
• Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

  2003cited by this paper
• Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.

  2003cited by this paper
• Killer Ig-Like Receptor Haplotype Analysis by Gene Content: Evidence for Genomic Diversity with a Minimum of Six Basic Framework Haplotypes, Each with Multiple Subsets1

  2002cited by this paper
• Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis.

  2002cited by this paper
• Neuroblastoma metastatic to the central nervous system

  2001cited by this paper
• Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma.

  2001cited by this paper
• Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults

  2001cited by this paper
• Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma.

  2000cited by this paper
• The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.

  1999cited by this paper
• Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.

  1998cited by this paper
• Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive?

  1997cited by this paper
• Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.

  1994cited by this paper
• Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study.

  1993cited by this paper
• Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

  1993cited by this paper
• Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment.

  1993cited by this paper
• Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells.

  1991cited by this paper
• Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.

  1987cited by this paper

• Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remission.

  2026cites this paper
• Factors Influencing Immunotherapy Response in Neuroblastoma: From Tumor Microenvironment to Combination Strategies

  2026cites this paper
• A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.

  2026cites this paper
• Neuroblastoma in Childhood: Biological Insights, Risk Stratification, and Advances in Multimodal Therapy

  2026influential citation
• A phase II trial of Naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in first complete remission.

  2025cites this paper
• GD2: hopes and challenges for the treatment of pediatric patients with tumors of the central nervous system

  2025cites this paper
• The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial

  2025cites this paper
• Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid

  2025cites this paper
• Prolonged overall survival in a child with multimetastatic retinoblastoma treated with anti-GD2 monoclonal antibody dinutuximab beta: a case report

  2025cites this paper
• The Role of Killer Ig-like Receptors in Diseases from A to Z

  2025cites this paper
• Evaluation of Minimal Residual Disease in Patients with Neuroblastoma

  2025cites this paper
• High-risk neuroblastoma in Mexico: from multimodal treatment to immunotherapy. Regarding the first case treated with naxitamab

  2025cites this paper
• Naxitamab plus stepped-up dosing of granulocyte–macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial

  2025influential citation
• Rapid COJEC without myeloablative therapy for high‐risk neuroblastoma

  2025cites this paper
• Clinical Significance of TERT Promoter Mutations in Neuroblastoma.

  2025cites this paper
• Case Report: Successful treatment of metastatic retinoblastoma with CNS involvement with anti-GD2 immunotherapy, intrathecal topotecan and reduced systemic chemotherapy

  2025cites this paper
• Dark NKnight rising: a current perspective on NK cell and CAR-NK cell therapy.

  2025cites this paper
• A pharmacological and clinical profile of Naxitamab for the treatment of high-risk neuroblastoma

  2025cites this paper
• Targeting TRIM59 impairs RNA splicing and promotes neuroblastoma differentiation and therapeutic responses

  2025cites this paper
• Latin American Consensus on the Use of Anti-GD2 Monoclonal Antibody Therapy in Patients With High-Risk Neuroblastoma.

  2025cites this paper
• The Neuroblastoma Microenvironment, Heterogeneity and Immunotherapeutic Approaches

  2024cites this paper
• Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges

  2024cites this paper
• Current and Emerging Biomarkers: Impact on Risk Stratification for Neuroblastoma.

  2024cites this paper
• Immunotherapies for Childhood Cancer.

  2024cites this paper
• Comprehensive quantifications of tumour microenvironment to predict the responsiveness to immunotherapy and prognosis for paediatric neuroblastomas.

  2024cites this paper
• Integrating multi-omics data reveals neuroblastoma subtypes in the tumor microenvironment.

  2024cites this paper
• Omalizumab for Treatment of Anti-GD2 Antibody-Related Urticaria.

  2024cites this paper
• Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology.

  2024cites this paper
• GD2-targeting therapy: a comparative analysis of approaches and promising directions

  2024cites this paper
• Prospects of anti-GD2 immunotherapy for retinoblastoma

  2024cites this paper
• Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives

  2024cites this paper
• Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells

  2024cites this paper
• Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer

  2024cites this paper
• Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review

  2024influential citation
• Arsenic trioxide induces ferroptosis in neuroblastoma by mediating GPX4 transcriptional inhibition

  2024cites this paper
• Extracellular vesicles in neuroblastoma: role in progression, resistance to therapy and diagnostics

  2024cites this paper
• Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma.

  2023cites this paper
• Targeting the myeloid microenvironment in neuroblastoma

  2023cites this paper
• Prognostic value of xenograft engraftment in patients with metastatic high‐risk neuroblastoma

  2023cites this paper
• Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report

  2023cites this paper
• GM‐CSF, G‐CSF or no cytokine therapy with anti‐GD2 immunotherapy for high‐risk neuroblastoma

  2023cites this paper
• Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System

  2023cites this paper
• Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges

  2023cites this paper
• Dinutuximab beta-targeted therapy kills beta-cell tumors of the pancreas

  2023cites this paper
• Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2

  2023cites this paper
• Stage 4N neuroblastoma before and during the era of anti‐GD2 immunotherapy

  2023influential citation
• Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors

  2023cites this paper
• Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial

  2023cites this paper
• A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood

  2023cites this paper
• New Approaches Towards Targeted Therapy for Childhood Neuroblastoma

  2023cites this paper
• Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells

  2023cites this paper
• Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial.

  2022cites this paper
• Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

  2022cites this paper
• MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment

  2022cites this paper
• Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies

  2022cites this paper
• Immunotherapy with anti‐GD2 monoclonal antibody in infants with high‐risk neuroblastoma

  2022cites this paper
• Immune checkpoint molecules in neuroblastoma: A clinical perspective.

  2022cites this paper
• Engaging plasticity: Differentiation therapy in solid tumors

  2022cites this paper
• Clinical Impact of KIR2DS3 and KIR2DL3 Genes in Neuroblastoma Patients

  2022cites this paper
• Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review

  2022cites this paper
• Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma

  2022cites this paper
• Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma

  2022cites this paper
• Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain

  2022cites this paper
• Bispecific antibodies for the treatment of neuroblastoma.

  2022cites this paper
• Clinical application of radioiodinated antibodies: where are we?

  2022cites this paper
• Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication

  2022cites this paper
• Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: experience of the Polish Paediatric Solid Tumours Study Group

  2022cites this paper
• Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1

  2022cites this paper
• Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives

  2022cites this paper
• Outcome of children with relapsed high-risk neuroblastoma in Japan and analysis of the role of allogeneic hematopoietic stem cell transplantation.

  2022cites this paper
• Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

  2021cites this paper
• Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies

  2021cites this paper
• KMT2A‐MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8‐year follow‐up

  2021cites this paper
• Re‐thinking transplant for neuroblastoma

  2021cites this paper
• Improved Outcomes with Induction Chemotherapy Combined with Arsenic Trioxide in Stage 4 Neuroblastoma: A Case Series

  2021cites this paper
• Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance

  2021cites this paper
• 131I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors

  2021cites this paper
• Naxitamab combined with granulocyte‐macrophage colony‐stimulating factor as consolidation for high‐risk neuroblastoma patients in complete remission

  2021cites this paper
• Monoclonal Antibody Therapies for High Risk Neuroblastoma

  2021cites this paper
• Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma

  2021cites this paper
• Effect of high-dose chemotherapy plus stem cell rescue on the survival of patients with neuroblastoma modified by MYCN gene gain/amplification and remission status: a nationwide registration study in Japan

  2021cites this paper
• Potent antitumor effect of T cells armed with anti‐GD2 bispecific antibody

  2021cites this paper
• Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients

  2021cites this paper
• Differentiating Neuroblastoma: A Systematic Review of the Retinoic Acid, Its Derivatives, and Synergistic Interactions

  2021cites this paper
• Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices

  2021cites this paper
• ISL1 promoted tumorigenesis and EMT via Aurora kinase A-induced activation of PI3K/AKT signaling pathway in neuroblastoma

  2021cites this paper
• Immunotherapy by anti-GD2 antibodies in patients with primary high-risk neuroblastoma, primary resistant and relapsed disease: Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg experience

  2021cites this paper
• Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma

  2021cites this paper
• Anti-GD2 antibody disrupts GD2:Siglec-7 interactions and synergizes with CD47 blockade to mediate tumor eradication

  2021cites this paper
• Role of immunotherapy in Ewing sarcoma

  2020cites this paper
• Novel anti-GD2 CAR-T cells exhibit superior cytotoxicity against neuroblastoma

  2020cites this paper
• Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma with Prior Disease Progression.

  2020cites this paper
• Anti-GD2 immunotherapy with the chimeric antibody ch14.18 for high-risk neuroblastoma

  2020cites this paper
• Bioinformatics Analysis Combined with Experiments to Explore Neuroblastoma Prognostic Indicators Based on Immune-related Genes.

  2020cites this paper
• Upfront consolidation treatment with 131I‐mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high‐risk neuroblastoma

  2020cites this paper
• Pulmonary Exacerbation of Undiagnosed Toxocariasis in Intensively-Treated High-Risk Neuroblastoma Patients

  2020cites this paper
• Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

  2020cites this paper
• Association of PARP1 polymorphisms with response to chemotherapy in patients with high‐risk neuroblastoma

  2020cites this paper
• GD2-направленная иммунотерапия нейробластомы группы высокого риска с использованием химерных антител ch14.18 immunotherapy with the antibody for high-risk neuroblastoma

  2020cites this paper
• Targets and Antibody Formats for Immunotherapy of Neuroblastoma

  2020influential citation